Median Tmax? [Regulatives / Guidelines]

posted by ratnakar1811 – India, 2008-04-04 07:35 (6661 d 17:20 ago) – Posting: # 1760
Views: 39,567

(edited on 2008-04-04 09:48)

Dear HS,

Thanks for your prompt reply, but the question remained unanswered that when we should exclude the subject from the study, is after bioanalysis or at the time of clinical phase only and if at the clininal phase what should be used as a basis for the same?

And as you have suggested considering the partial area, how it should be done practically?

Best Regards,

Ratnakar
--
Edit: Full quote removed. Please see this post! [Ohlbe]

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,571 registered users;
180 visitors (0 registered, 180 guests [including 44 identified bots]).
Forum time: 00:55 CEST (Europe/Vienna)

It requires a very unusual mind
to undertake the analysis of the obvious.    Alfred North Whitehead

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5